Theravance Biopharma (TBPH) Share-based Compensation (2013 - 2026)

Theravance Biopharma (TBPH) has reported Share-based Compensation for 14 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 415.33% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $22.1 million (up 29.74% YoY), while the FY2025 annual figure was $18.5 million, down 28.25% from the prior year.
• Share-based Compensation retreated to $4.5 million in Q1 2026 per TBPH's latest filing, from $16.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $16.4 million in Q4 2025 and bottomed at -$17.0 million in Q4 2023.
• Historically, Share-based Compensation has averaged $4.7 million across 5 years, with a median of $5.8 million in 2024.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 345.28% — and 2024, when it soared 489.52%.
• Theravance Biopharma's Share-based Compensation stood at $7.0 million in 2022, then tumbled by 345.28% to -$17.0 million in 2023, then jumped by 134.18% to $5.8 million in 2024, then jumped by 181.86% to $16.4 million in 2025, then slumped by 72.57% to $4.5 million in 2026.
• Business Quant data shows TBPH's Share-based Compensation at $4.5 million in Q1 2026, $16.4 million in Q4 2025, and -$7.4 million in Q3 2025.